Market Overview

Isis Pharma Issues Update on CHMP Opinion on KYNAMRO

Share:
Related ISIS
Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease
ISIS Pharma Still Undervalued, Needham Says
AstraZeneca Beats on Q2 Earnings, Revises Revenue View - Analyst Blog (Zacks)

Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that following Genzyme's request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) confirmed its previous position and has maintained a negative opinion regarding the marketing authorization application (MAA) for KYNAMRO^TM (mipomersen) as a treatment for patients with Homozygous Familial Hypercholesterolaemia (HoFH).

The FDA approved KYNAMRO in the United States in January 2013 for the treatment of patients with Homozygous Familial Hypercholesterolaemia.

Posted-In: News

 

Related Articles (ISIS)

Get Benzinga's Newsletters